Author

G. van Roey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

H. Schuitemaker· 2 shared J. Sadoff· 2 shared M. Le Gars· 2 shared B. Brandenburg· 1 shared C. Crowther· 1 shared D. Veldman· 1 shared D. Zuijdgeest· 1 shared F. Ayres· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. Schuitemaker

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintJul 1, 2021

Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

M. Jongeneelen, K. Kaszas, D. Veldman…·B. Brandenburg

This study evaluates the neutralizing activity of Ad26.COV2.S vaccine sera against SARS-CoV-2 variants, finding reduced effectiveness against Beta and Gamma but less reduction against Delta.

DOI 10.1101/2021.07.01.450707

experimental assayhost-pathogen & immune response

𝕏 PostBluesky

ImmunologybioRxivPreprintJun 9, 2021

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

P. Moore, T. Moyo, T. Hermanus…·G. Gray

The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.

DOI 10.1101/2021.06.09.447722

humanproteomics

𝕏 PostBluesky